INS and COVID-19: Treatment with insulin, antiplatelets and PPI were associated with increased risk of COVID-19-related mortality (aOR 1.41, 95% CI 1.04–1.90; aOR 1.29, 95% CI 1.01–1.64; and aOR 1.47, 95% CI 1.15–1.88).